ELEMENT-MDS

Phase 3 Clinical Trial Comparing Luspatercept VS Epoetin Alfa in Patients with Very Low – Intermediate Risk MDS Who Are Not Transfusion Dependent

What's the purpose of the trial?

Researchers are hoping to learn more about the differences in how the drug, luspatercept, may help to prevent or delay the need for red blood cell (RBC) transfusions when compared to epoetin alfa in patients with myelodysplastic syndrome (MDS). 

Trial status

Accepting patients

Phase
Phase 3
Enrollment
360
Last Updated
2 weeks ago
Am I Eligible

Participating Centers

There are 29 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Epoetin Alfa is a bone marrow stimulant medication used to treat anemia in several different indications. 
  • Luspatercept is an agent that helps your bone marrow finish making red blood cells that have started to form.

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

Luspatercept

Accepting patients

Epoetin Alfa

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.